Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Ted White will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that President and CEO Ted White will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 p.m. ET. The presentation will include insights into Verrica's dermatology therapeutics, especially their late-stage product candidates, VP-102 for treating molluscum and warts, and VP-103 for plantar warts. Additionally, Verrica has a global license agreement with Lytix Biopharma for developing LTX-315 for dermatologic oncology.
Positive
- Ted White will present at a major healthcare conference, increasing visibility.
- Verrica focuses on significant unmet needs in dermatology with late-stage candidates VP-102 and VP-103.
Negative
- None.
Details
News Market Reaction – VRCA
The recorded move for VRCA in the trading session of this news was +3.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. ET.
Participants may access a live webcast of the event through the following link:
https://event.on24.com/wcc/r/3173547/7EB680169FF01818435F231AA17B51A2.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, Visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
A. Brian Davis
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com
William Windham
Solebury Trout
646.378.2946
wwindham@soleburytrout.com
Media:
Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@soleburytrout.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.